Insugen R (recombinant human insulin biosimilar) / Biocon - LARVOL DELTA

[VIRTUAL] Safety and Effectiveness of Recombinant Human Insulin Insugen in Real-World Clinical Setting (ADA 2020) - "Continuing patient education and support programmes with rHI are critical role players in improving the access and overall disease management.Objective: This is a non-interventional study to observe the safety and effectiveness of Recombinant Human insulin in a real world population with type 2 (T2DM) diabetes mellitus from Indian perspective.Methodology: Out of 10426 diabetes patients who were enrolled in patient support program i.e “Insulin Therapy Assistance Program (iTAP)”, 5691 patients were initiated with various formulations of rHI (Insugen R, N, 30/70 and 50/50)... In the current study, various formulations of rHI were well tolerated and resulted in significant reduction of HbA1c, FPG and PPG when aided with patient support program. Considering the economic impact of diabetes patients in taking insulins, human insulin become an alternative option in comparison to analogues which are expensive. Early initiation of insulin therapy can prevent or delay diabetes..."

Clinical • Real-World Evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus